2024-520346-39-00招募中2 期
A randomised, double-blind, multicenter, placebo-controlled clinical trial of colchicine to reduce coronary artery inflammation in people with HIV. COLCOHIV
Fundacion Para La Investigacion Biomedica Del Hospital Universitario La Paz4 个研究点 分布在 1 个国家目标入组 104 人开始时间: 2025年4月25日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 104
- 试验地点
- 4
- 主要终点
- Percent change from baseline of the mean Fat Attenuation Index (FAI) score for the 3 coronary arteries (RCA, LAD, LCX), calculated as the average of the analyzable FAI scores (valid baseline and post-baseline FAI score) across the three main coronary arteries
研究概览
简要总结
To assess the impact of colchicine versus placebo in reducing coronary artery inflammation in PWH over 50 years and high cardiovascular risk after 96 weeks
研究设计
- 分配方式
- Randomized
- 主要目的
- Phase II, randomised, multicentre, double-blind, placebo-controlled, proof of concept trial
- 盲法
- Double (Investigator, Subject)
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- •PWH > 50 years old
- •High cardiovascular risk measured by SCORE-2 > 5%
- •Stable antiretroviral therapy (ART) in the previous six months
- •Viral load < 50 copies/mililiter for at least 1 year. One blip is allowed (Viral load between 20-200 copies/mililiter with a previous and after viral load determinations < 20 copies per mililiter.
- •CD4 cell count > 350 cells/mm3
- •Stable dose of an intermediate or high intensity statin in the previous year (statin dose should not be modified throghout the study unless there is a robust clinical indication). In case the participant does not receive statins, all other hypolipemiants (bempedoic acid, ezetimibe) will need to be at a stable dose as well in the previous year.
- •No clinical indication for a change in treatment based on European Society of Cardiology Guidelines
- •Written informed consent obtained according to international guidelines and local laws
- •Ability to understand the nature of the trial and the trial related procedures and to comply with them
排除标准
- •Severe Heart failure defined as LVEF < 35%.
- •Renal dysfunctions defined as eGFR < 50 ml/min or serum creatinine levels > 1.7 mg/dL
- •Severe hepatic impairments defined as a Child-Pugh category C
- •Levels of ALT over five times the upper limit of normal OR levels of ALT over three times the upper limit of normal AND bilirrubin levels over one point five times the upper limit of normal
- •Participant is receiving drugs that inhibit the CYP3A4 (e.g. Verapamil, Azithromycin, Clarithromycin, protease inhibitors, cobicistat), CYP2D6 or inhibitors of P-glycoprotein.
- •Participant needs treatment with colchicine for any indication
- •Participants with stomach ulcers or gastrointestinal bleeding
- •Participants with highly elevated hsCRP > 10 mg/dL at screening
- •Women of childbearing potential. - Permanent sterilisation methods including hysterectomy, bilateral salpingectomy and bilateral oophorectomy. - Postmenopausal state, defined as no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a post-menopausal state in women not using hormonal contraception or hormonal replacement therapy. However in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient. - Male participants are considered fertile after puberty unless permanently sterile by bilateral orchiectomy. To prevent pregnancies in female partners of male participants, they must agree to use highly effective contraceptive methods or have practiced sexual abstinence during the treatment period and until the end of relevant systemic exposure, defined as 5 half-lives of the IMP (9 days approximately).
- •Known hypersensitivity to the active substances or any of the excipients
- •Known iodine contrast allergy with prior history of anaphylaxis
- •Patient without legal capacity who is unable to understand the nature, significance and consequences of the trial
- •Previous MI, stroke or coronary by-pass surgery
- •History of non-cutaneus malignancy prior to enrollment
- •History of inflammatory bowel disease or chronic diarrhoea
结局指标
主要结局
Percent change from baseline of the mean Fat Attenuation Index (FAI) score for the 3 coronary arteries (RCA, LAD, LCX), calculated as the average of the analyzable FAI scores (valid baseline and post-baseline FAI score) across the three main coronary arteries
Percent change from baseline of the mean Fat Attenuation Index (FAI) score for the 3 coronary arteries (RCA, LAD, LCX), calculated as the average of the analyzable FAI scores (valid baseline and post-baseline FAI score) across the three main coronary arteries
次要结局
- Changes in plaque volume and plaque burden assessed by CCTA in week 96.
- Changes in plaque morphology (non-calcified, mixed, calcified) assessed by CCTA in week 96
- Changes in the percentage of high-risk plaques (positive remodelling, spotty calcium, napky ring sign and low attenuation plaque) assessed by CCTA in week 96
- Changes in serum inflammatory markers (hsPCR, IL-6, IL-1 beta, IL-18, SuPAR) in week 96
- Changes in inflammasome markers in extracellular vesicles (NLRP3, ASC, Caspase-1) in week 96
- Changes in differential monocytes subpopulations (classic CD14++CD16-, non-classic CD14++CD16++ and intermediate CD14+CD16+) in week 96
- Percentage change of leukocyte count in week 96
- Solicited and unsolicited AEs in all participants throughout the trial
- Serious adverse events (SAEs) in all participants
- Change from baseline for FAI, FAI score (mean absolute change and mean percent change) and FAI score centile in the following vessels: Greatest change in most inflamed vessel, Greatest change in any vessel , RCA only analysis, LAD only analysis, LCX only analysis
- Mean absolute change from baseline for mean FAI and mean FAI score, defined as the average of the analyzable vessels (with valid baseline FAI and post-baseline FAI) across the three main coronary arteries (RCA, LAD, LCX)
- Differences in FAI percentage change between males and females in both treatment groups assessed by CCTA in week 96
- Differences in FAI percentage change by CYP2D6 genotype in the treatment group
- Differences in MACE between colchicine and placebo groups assessed clinically in week 96
- Change from baseline for CaRi-Heart risk score (mean absolute change and mean percent change.
研究者
Jose Ignacio Bernardino de la Serna
Scientific
Fundacion Para La Investigacion Biomedica Del Hospital Universitario La Paz
研究点 (4)
Loading locations...
相似试验
进行中（未招募）
1 期
Colchicine Cardiovascular Outcomes Trialpatients with atherosclerotic coronary artery disease (CAD)EUCTR2014-005172-28-PTMontreal Heart Institute4,500
进行中（未招募）
1 期
Colchicine Cardiovascular Outcomes Trialpatients with atherosclerotic coronary artery disease (CAD)EUCTR2014-005172-28-ESMontreal Heart Institute4,500
进行中（未招募）
1 期
Colchicine Cardiovascular Outcomes Trialpatients with atherosclerotic coronary artery disease (CAD)EUCTR2014-005172-28-FRMontreal Heart Institute4,500
招募中
1 期
Colchicine Effect on Perivascular Inflammation Index on Coronary CTAInflammatory ResponseCoronary DiseaseAtherosclerosisNCT05347316University of Sao Paulo General Hospital40
进行中（未招募）
1 期
COLCOT Studypatients with atherosclerotic coronary artery disease (CAD)MedDRA version: 20.0Level: HLGTClassification code 10011082Term: Coronary artery disordersSystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 20.0Level: PTClassification code 10028596Term: Myocardial infarctionSystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 20.0Level: SOCClassification code 10007541Term: Cardiac disordersSystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 20.0Level: HLTClassification code 10011085Term: Ischaemic coronary artery disordersSystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 20.0Level: LLTClassification code 10028595Term: Myocardial infarctSystem Organ Class: 10007541 - Cardiac disordersEUCTR2014-005172-28-ITMONTREAL HEART INSTITUTE4,500